Adam Feuerstein is an American blogger and columnist covering the biotechnology sector.
Education[edit]
Adam Feuerstein completed a bachelor's degree in political science at Emory University.[1]
Career[edit]
Feuerstein covered business, technology, and commercial real estate for the San Francisco Business Times and the Atlanta Business Chronicle as an assistant managing editor.[1][2] He later wrote about business software for Upside.com. In March 2001, he joined TheStreet.com. From 2005 to 2006 he worked as a research analyst for a hedge fund before returning to TheStreet. He resigned in May 2017. Feuerstein accepted a position as a national biotechnology columnist at STAT in June 2017.[1]
Feuerstein is known for his style of reporting and his tweets to his large Twitter following.[3][4] He often shares "unabashed" views on Biotech stock and the Food and Drug Administration.[5]
References[edit]
- ^ a b c Roush, Chris (May 30, 2017). "TheStreet's Feuerstein leaving for STAT". Talking Biz News. Retrieved 2018-11-23.
- ^ "Adam Feuerstein Preps for Move to STAT". Cision. June 1, 2017. Retrieved 2018-11-23.
- ^ Robbins, Rebecca (May 2, 2016). "Is Adam Feuerstein the most feared man in biotech?". STAT. Retrieved 2018-11-23.
- ^ Valleskey, Brianna (November 14, 2014). "How Adam Feuerstein Follows The Biotech Sector". Benzinga. Retrieved 2018-11-23 – via Yahoo.
- ^ Schifrin, Matthew (2010-10-01). The Warren Buffetts Next Door: The World's Greatest Investors You've Never Heard Of and What You Can Learn From Them. John Wiley & Sons. p. 88. ISBN 9780470915301.